Cell – Page 11 – Talk Bio

Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies

1 year ago talkbio0Tagged Ataxia Telangiectasia Mutated Proteins, Catalio Capital Management, cellular targeting, CEO, CLASRP gene, engagers, financing characteristics, HLA Molecule Profiling, Holdings, Personalized Off-the-Shelf Therapies, Robert Ross, T-Lymphocyte, Third Rock

Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross

Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks

2 years ago talkbio0Tagged Accelerated, Antibodies, Bispecific, Approved, BeiGene, Brukinsa, Chimeric Antigen Receptor T-cells, Clinical Trials, Combined Modality Therapy, competition, Disease Progression, Gazyva, Lymphoma, Follicular, obinutuzumab, ORR, Overall response rate, Rosewood, Toxicity aspects, United States Food and Drug Administration, zanubrutinib

Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies

FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma

2 years ago talkbio0Tagged Amtagvi, Lymphocytes, Tumor-Infiltrating, Solid Neoplasm, United States Food and Drug Administration

Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating